Laboratory Corporation of America Holdings (LH) Receives Analyst Rating

Laboratory Corporation of America Holdings (LH) has an average broker rating of 1.54, which is interpreted as a Buy, as rated by 14 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Laboratory Corporation of America Holdings (LH) : The highest level Laboratory Corporation of America Holdings (LH) is projected to reach is $160 for the short term and the lowest estimate is at $132. The consolidated price target from 13 rating analysts who initiate coverage on the stock is $148.42 and the possibility the share price can swing is $9.42.


Also, Citigroup initiates coverage on Laboratory Corporation of America Holdings (NYSE:LH) . The global brokerage major announces a current price target of $156 per share. Analysts at the Citigroup have a current rating of Neutral on the shares. The rating by the firm was issued on September 9, 2016.

Laboratory Corporation of America Holdings (NYSE:LH): After opening at $133.06, the stock dipped to an intraday low of $132.575 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $135.265 and the buying power remained strong till the end. The stock closed at $134.68 for the day, a gain of 1.27% for the day session. The total traded volume was 631,321. The stocks close on the previous trading day was $132.99.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.